Article Text

PDF

FRI0056 Tnfalpha therapy initiation audit: rationing on an equitable basis – the norfolk and norwich (n/n) experience
  1. MF Somerville,
  2. A Price-Forbes,
  3. A Brooksby,
  4. J Leeder,
  5. JK Gaffney,
  6. P Merry,
  7. DG Scott
  1. Rheumatology, Norfolk and Norwich University Hospital NHS Trust, Norwich, UK

Abstract

Background BSR1 and EULAR2 consensus guidelines have been published regarding the evolving use of TNF@ therapy in rheumatoid arthritis (RA). It is anticipated that demand will exceed supply. Norfolk Health Authority has allocated £210,000 (for approximately 30 patients) for initiation of this treatment during 2000–01. An initial review highlighted discrepancies between the DAS28 (ie consensus guidelines), and our individual clinical assessment of patients.

Objectives To evaluate prospectively a cohort of consecutive eligible patients, prioritise them according to a weighted scoring system, which we developed and observe changes in the profile of those fulfilling these revised criteria for treatment.

Methods In a 3 month period, potential patients were recruited to an assessment clinic. Those fulfilling the criteria were further stratified using a 5- point cumulative scoring system based on 4 variables: 1) DAS28, 2) Age, 3) Disease duration and 4) Steroid dose. This weighted towards younger patients with shorter disease duration, requiring steroids and having a high DAS28, on the assumption that treating such patients would be more cost-effective. This resulted on a final list of 30 patients selected for treatment (N/N Priority).

Results 135 out of 139 patients assessed, fulfilled the BSR eligibility criteria. Nearly two thirds of the 30 patients with the highest DAS28 (BSR priority) were subsequently replaced on our stratified list (N/N Priority). However, funding is still not available for 78% of our patients, who are otherwise eligible for treatment.

Abstract FRI0056 Table 1

Conclusion Rationing creates difficult choices. We have attempted to select patients according to need and cost effectiveness. These decisions should be debated openly as they have important implications for health policy and clinical management.

References

  1. British Society for Rheumatology – Report of a Working Party, April 2000

  2. Updated consensus statement on TNF blocking drugs for the treatment of RA. Ann Rheum Dis. 2000;59(Suppl I):i1–i2

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.